AI for open-ended scientific explanations

LLM Kernel, a framework for evaluating explanatory reasoning

Oct 31 • 

Transcripta Bio

, 

Will Connell

, and 

Clayton Mellina

4

1

Using LLMs to group pathways by function

An exploration of contextual pathway analysis.

Oct 25 • 

Transcripta Bio

3

1

September 2025

Accelerating Drug Discovery with Transcriptomics: A Case Study

By using dense transcriptomic signatures of diseases matched with transcriptomic signatures of drugs, Transcripta is able to rapidly find effective new…

Sep 23 • 

Transcripta Bio

2

1

May 2025

Transcripta Bio collaborates with Microsoft Research to Advance AI-Driven Disease-Gene Discovery

Palo Alto, CA – May 28, 2025 - Transcripta Bio today announced a research collaboration with Microsoft Research to accelerate the discovery of…

May 28 • 

Transcripta Bio

2

1

Transcripta Bio's new visual brand language

Introducing Eigenfish: our new brand imagery

May 6 • 

Transcripta Bio

 and 

Clayton Mellina

1

April 2025

Mastering the transcriptome with artificial intelligence

Chemo-transcriptomics at scale

Apr 16 • 

Transcripta Bio

2

Transcripta Bio Named to the TIME100 Most Influential Companies of 2024

Palo Alto, Calif., May 30, 2024 – Transcripta Bio, a platform drug development biotechnology company that is revolutionizing discovering and developing…

Apr 16 • 

Transcripta Bio

1

Unveiling Transcripta Bio

Today we are unveiling Transcripta Bio.

Apr 16 • 

Transcripta Bio

1

Rarebase Names Chris Moxham as Chief Executive Officer

See full press release on PR Newswire.

Apr 16 • 

Transcripta Bio

1